Our team in Poland has developed, following more than 15 years of laboratory and clinical research, an advanced stabilized mitochondrial ATP preparation.
The ATP formulation is loaded into our proprietary Titanium-Tungsten nanostructures created with phosphate bonds using ultrasonic cavitation. This nanotechnology-based delivery system markedly enhances molecular stability and enables deeper penetration and more uniform distribution of the ATP solution further into the intestinal tract, optimizing bioavailability and systemic cellular uptake.
Independent laboratory testing (IMD Labor (Berlin), Laborarztpraxis Rhein-Main (Frankfurt) confirms increases in blood intracellular ATP exceeding 170 % (from 2.79 µM at the lower reference range to 7.59 µM at the upper reference range after approximately 6 weeks of daily 50 ml oral administration), with beneficial effects persisting even after discontinuation. In granulocytes, key immune effector cells, intracellular ATP levels rose by 105.5 % (male subject) and 121.3 % (female subject) after two months.
This targeted mitochondrial support promotes biogenesis, enhances oxidative phosphorylation, reduces reactive oxygen species, activates NRF2 pathways, and facilitates cellular repair and regeneration. In clinical observations involving patients with metastatic cancer, autoimmune disorders, thyroid and prostate conditions, and neurological diseases, these substantial ATP elevations have been associated with marked symptom improvement and, in many cases, reversal of disease markers — typically within months. Detailed laboratory reports, scientific mechanisms, and medical outcome data are available at
atp-therapy.com